RecruitingNot ApplicableNCT06802120

Effects of Osteopathic Management on Disability and Quality of Life After Lumbar Arthrodesis

Effects of Osteopathic Management on Disability and Quality of Life After Lumbar Arthrodesis. A PARALLEL, RANDOMIZED AND DOUBLE-BLIND CONTROLLED PILOT STUDY


Sponsor

Clinique Bizet

Enrollment

40 participants

Start Date

Jan 2, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of our study is to assess the effect of a combined physiotherapy and osteopathy treatment versus a placebo on the management of disability and quality of life after lumbar arthrodesis. This study will provide a better assessment of the use of osteopathy as a non pharmacological approach to post-operative management. For this purpose, We will analyze the effects of these two approaches, targeted and non-targeted osteopathy (TO vs. NTO), on patients' disability and quality of life after surgery.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria3

  • having experienced a lumbar arthrodesis (of one to three levels) four weeks before inclusion
  • being under a stable pharmacological treatment over the last month
  • who are suffering from postoperative mechanical pain (VAS ≥ 4)

Exclusion Criteria6

  • neuropathic pain according to a DN4 score greater than or equal to 4/10,
  • are suffering from fibromyalgia,
  • algodystrophy,
  • other somatic or neuropsychiatric diseases (other than depression and anxiety),
  • have received osteopathic treatment over the last three month prior to inclusion,
  • are included in another interventional research protocol during the study period

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERosteopathy real

treatment with real osteopathy 2 times a week for 8 weeks

OTHERsham osteopathy

treatment with sham osteopathy 2 times a week for 8 weeks


Locations(1)

Clinique Bizet

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06802120


Related Trials